



CORRECTION

Correction: Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells

H Hirata¹, Y Hinoda², V Shahryari¹, G Deng¹, Y Tanaka¹, Z L Tabatabai³ and R Dahiya¹

British Journal of Cancer (2018) 119:388; <https://doi.org/10.1038/s41416-018-0146-2>

Correction to: *British Journal of Cancer* **110**, 1645–1654 (2014); <https://doi.org/10.1038/bjc.2014.48>; published online 6 February 2014

version. The correct version of Fig. 4 with the original pictures for both PC3 miR-NC inh-0h and PC3-miR1260b inh-0h are provided below.

The authors report that there is a mistake in the representative picture of Fig. 4D (top row: PC3-miR1260b inh-0h) in the original




Fig. 4 Effect of miR-1260b knockdown on prostate cancer cells (PC-3, DU-145). Two prostate cancer cell lines (PC-3 and DU-145) were transiently transfected with either miR-1260b inhibitor or miR-negative control (miR-NC inhibitor). **a** Relative miR-1260b expression (miR-NC inhibitor or miR-1260b inhibitor transfected PC cells), **b** cell viability assay (miR-NC inhibitor or miR-1260b inhibitor transfected PC cells), **c** invasion assay, **d** wound healing assay (16–17 h). **e** Apoptosis assay, **f** cell cycle analysis, **g** TCF reporter assay. Error bars represent \pm s.d.

¹Department of Urology, San Francisco Veterans Affairs Medical Center and University of California at San Francisco, San Francisco, CA, USA; ²Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan and ³Department of Pathology, San Francisco Veterans Affairs Medical Center and University of California at San Francisco, San Francisco, CA, USA

Correspondence: R Dahiya (rdahiya@urology.ucsf.edu)